menu
    • menu
    [{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Zydus Lifesciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Hyoscine Hydrobromide

    Menu

    Hyoscine Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zydus Lifesciences

                            India arrow
                            DDL Conference
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences Gets USFDA Nod to Market Scopolamine Transdermal System

                            Details : Scopolamine hydrobromide is a mAChRs inhibitor. which is indicated to prevent nausea and vomiting under different circumstances.

                            Brand Name : Scopolamine HBr-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2024

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Gets Complete Response Letter from FDA for Intranasal Scopolamine

                            Details : DPI-386 (scopolamine hydrobromide) is a mAChRs inhibitor which is being evaluated in phase 3 clinical trials for the treatment of motion sickness in adults.

                            Brand Name : DPI-386

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2024

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : National Aeronautics and Space Administration

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-38...

                            Details : DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Brand Name : DPI-386

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : National Aeronautics and Space Administration

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Accepts Defender Pharmaceuticals™ New Drug Application for Intranasal Scopolamine Gel

                            Details : DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Brand Name : DPI-386

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Announces Submission of New Drug Application to FDA with Intranasal Scopolamine for P...

                            Details : DPI-386 (scopolamine hydrobromide) intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Brand Name : DPI-386

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 26, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Defender Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolam...

                            Details : DPI-386 (scopolamine hydrobromide) Intranasal gel, which is in late-stage development for the prevention of nausea and vomiting induced by motion sickness.

                            Brand Name : DPI-386

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : Scopolamine Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth